Company intelligence / Profile preview

Sangrail Biologics

Rockville, Maryland, USA

Ownership: Private
Employees: ~15
Development stage: Other

Overview

Sangrail Biologics is a biotechnology company focused on developing next-generation biologics for the treatment of cancer and autoimmune disorders. The company utilizes its proprietary protein engineering platform to design molecules with enhanced therapeutic windows and reduced side effects compared to traditional biologics. Its lead programs target the CD47/SIRPα axis, aiming to harness the innate immune system to combat various malignancies. Sangrail is headquartered in Rockville, Maryland, and is led by a team of experts in immunology and protein chemistry.

Therapeutic areas: OncologyImmunology
Modalities: Recombinant fusion proteinMonoclonal antibodyCytokineBiologic
Industry: Biotech

Beyond the preview

Go deeper on Sangrail Biologics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sangrail Biologics.

Explore the full profile